Autolus Therapeutics
AUTL
84 hedge funds and large institutions have $184M invested in Autolus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.84% less ownership
Funds ownership: 52.36% → 50.51% (-1.8%)
6% less funds holding
Funds holding: 89 → 84 (-5)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
33% less capital invested
Capital invested by funds: $277M → $184M (-$92.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$5.49M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.48M |
| 3 |
MG
Marex Group
London,
|
+$825K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$651K |
| 5 |
Millennium Management
New York
|
+$311K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.35M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.7M |
| 3 |
AC
Armistice Capital
New York
|
-$2.58M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.33M |
| 5 |
Renaissance Technologies
New York
|
-$1.22M |
AUTL Hedge Fund Activity: Q1 2026 in Review
84 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2026, worth a combined $184M — down 33% from $277M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AUTL and 9 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 22 added.
The largest buyer was MAK Capital One, adding an estimated $5.49M. The largest seller was BlackRock, cutting an estimated $3.35M.
- 84 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2026, down from 89 in Q4 2025.
- Funds reported $184M of Autolus Therapeutics stock for Q1 2026, down 33% quarter-over-quarter.
- 9 funds opened new Autolus Therapeutics positions in Q1 2026 and 13 closed out, a net change of -4 holders.
- The largest Autolus Therapeutics buyer in Q1 2026 was MAK Capital One, an estimated $5.49M added.
- The largest Autolus Therapeutics seller in Q1 2026 was BlackRock, an estimated $3.35M sold.
Based on aggregated 13F filings for Q1 2026.